评估使用固定剂量与可变剂量的4因子前列红素复合物缩剂在抗凝剂相关的大型出血中的使用
Elizabeth Schrader1, Brianna Zinser1, Ashish Kulhari1
1Research Medical Center, Kansas City, MO, United States.
The American journal of emergency medicine
|October 17, 2025
概括
固定的剂量4-因子前列红素复合缩物 (4F-PCC) 显示出可比的静血疗效与可变剂量用于与抗凝剂相关的大型出血. 这种固定剂量方法也导致治疗成本显著降低.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 四因子前列红素复合缩物 (4F-PCC) 对于在重大出血事件中逆转抗凝作用至关重要.
- 固定剂量4F-PCC在降低成本和简化管理方面提供了潜在的好处.
- 评估固定剂量与可变剂量对于优化患者护理和资源配置至关重要.
研究的目的:
- 为了比较固定剂量与可变剂量4F-PCC在实现血液静止方面的有效性.
- 在因维生素K抗剂 (VKA) 和直接因子Xa (FXa) 抑制剂而导致严重出血的患者中评估静血疗效.
- 分析固定剂量4F-PCC的成本效益.
主要方法:
- 追溯队列研究涉及接受4F-PCC的患者.
- 从2018年1月1日到2023年8月31日收集的数据.
- 主要结局:由国际血栓形成学会和血液静止学会定义的有效血液静止标准.
主要成果:
- 有效的静血率相似:57%的固定剂量和53%的可变剂量4F-PCC.
- 固定的剂量组中的血栓栓塞发事件较低 (4.2%),相比于可变剂量组 (10.6%).
- 固定剂量 (7023美元) 与可变剂量 (11311美元) 的平均成本明显较低.
结论:
- 固定剂量4F-PCC在主要抗凝固剂相关出血中对静血效果与可变剂量4F-PCC同样有效.
- 固定剂量策略提供了显著的成本优势.
- 结果在各种出血类型和严重程度上一致.
相关概念视频
Venous Thrombosis III: Interprofessional Care
278
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
278
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Venous Thrombosis IV: Nursing Management
192
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
192
Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Disorders of Hemostasis
2.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.0K


